Displaying 25 - 36 of 36
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Displaying 25 - 36 of 36